BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21403900)

  • 1. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.
    Dunne MR; Mangan BA; Madrigal-Estebas L; Doherty DG
    Mediators Inflamm; 2010; 2010():704941. PubMed ID: 21403900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons.
    Boullier S; Poquet Y; Debord T; Fournie JJ; Gougeon ML
    Eur J Immunol; 1999 Jan; 29(1):90-9. PubMed ID: 9933090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (E)-4-hydroxy-3-methyl-but-2 enyl pyrophosphate-stimulated Vgamma9Vdelta2 T cells possess T helper type 1-promoting adjuvant activity for human monocyte-derived dendritic cells.
    Dunne MR; Madrigal-Estebas L; Tobin LM; Doherty DG
    Cancer Immunol Immunother; 2010 Jul; 59(7):1109-20. PubMed ID: 20306041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
    Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
    J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of tumour necrosis factor-alpha and interleukin-12 on isopentenyl pyrophosphate-stimulated interferon-gamma production by cord blood Vgamma9 T cells.
    Campos Alberto EJ; Shimojo N; Aoyagi M; Kohno Y
    Immunology; 2009 Jun; 127(2):171-7. PubMed ID: 19019091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-18 activates Vγ9Vδ2
    Murday AS; Chaudhry S; Pauza CD
    Immunology; 2017 Aug; 151(4):385-394. PubMed ID: 28342224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype.
    Wesch D; Glatzel A; Kabelitz D
    Cell Immunol; 2001 Sep; 212(2):110-7. PubMed ID: 11748927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.
    Sicard H; Ingoure S; Luciani B; Serraz C; Fournié JJ; Bonneville M; Tiollier J; Romagné F
    J Immunol; 2005 Oct; 175(8):5471-80. PubMed ID: 16210655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.
    Moulin M; Alguacil J; Gu S; Mehtougui A; Adams EJ; Peyrottes S; Champagne E
    Cell Mol Life Sci; 2017 Dec; 74(23):4353-4367. PubMed ID: 28669030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-presenting effects of effector memory Vγ9Vδ2 T cells in rheumatoid arthritis.
    Hu C; Qian L; Miao Y; Huang Q; Miao P; Wang P; Yu Q; Nie H; Zhang J; He D; Xu R; Chen X; Liu B; Zhang D
    Cell Mol Immunol; 2012 May; 9(3):245-54. PubMed ID: 22139198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
    Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpaca (
    Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity.
    Spencer CT; Abate G; Blazevic A; Hoft DF
    J Immunol; 2008 Oct; 181(7):4471-84. PubMed ID: 18802050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of alpha beta and gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate.
    Wesch D; Marx S; Kabelitz D
    Eur J Immunol; 1997 Apr; 27(4):952-6. PubMed ID: 9130649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
    Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
    J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
    Lafont V; Liautard J; Liautard JP; Favero J
    J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
    Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
    Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-fibrotic characteristics of Vγ9+ γδ T cells in systemic sclerosis.
    Markovits N; Bendersky A; Loebstein R; Brusel M; Kessler E; Bank I
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):23-29. PubMed ID: 26886502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated γδ T lymphocytes.
    Rosso DA; Rosato M; Iturrizaga J; González N; Shiromizu CM; Keitelman IA; Coronel JV; Gómez FD; Amaral MM; Rabadan AT; Salamone GV; Jancic CC
    J Neurooncol; 2021 Jul; 153(3):403-415. PubMed ID: 34125375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.